ATE289508T1 - Butyrate derivaten zur behandlung von fibromyalgia und chronische müdigkeit-syndrom - Google Patents

Butyrate derivaten zur behandlung von fibromyalgia und chronische müdigkeit-syndrom

Info

Publication number
ATE289508T1
ATE289508T1 AT98941094T AT98941094T ATE289508T1 AT E289508 T1 ATE289508 T1 AT E289508T1 AT 98941094 T AT98941094 T AT 98941094T AT 98941094 T AT98941094 T AT 98941094T AT E289508 T1 ATE289508 T1 AT E289508T1
Authority
AT
Austria
Prior art keywords
fibromyalgia
chronic fatigue
treatment
fatigue syndrome
butyrate derivatives
Prior art date
Application number
AT98941094T
Other languages
English (en)
Inventor
Martin B Scharf
Original Assignee
Orphan Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orphan Medical Inc filed Critical Orphan Medical Inc
Application granted granted Critical
Publication of ATE289508T1 publication Critical patent/ATE289508T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98941094T 1997-08-29 1998-08-27 Butyrate derivaten zur behandlung von fibromyalgia und chronische müdigkeit-syndrom ATE289508T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/920,979 US5990162A (en) 1997-08-29 1997-08-29 Method for treatment of fibromyalgia and chronic fatigue syndrome
PCT/US1998/017818 WO1999009972A1 (en) 1997-08-29 1998-08-27 Butyrate derivatives in the treatment of fibromyalgia and chronic fatigue syndrome

Publications (1)

Publication Number Publication Date
ATE289508T1 true ATE289508T1 (de) 2005-03-15

Family

ID=25444733

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98941094T ATE289508T1 (de) 1997-08-29 1998-08-27 Butyrate derivaten zur behandlung von fibromyalgia und chronische müdigkeit-syndrom

Country Status (15)

Country Link
US (1) US5990162A (de)
EP (1) EP1017381B1 (de)
JP (1) JP3660587B2 (de)
AT (1) ATE289508T1 (de)
AU (1) AU737086B2 (de)
CA (1) CA2301723C (de)
CZ (1) CZ295248B6 (de)
DE (1) DE69829112T2 (de)
ES (1) ES2235355T3 (de)
HK (1) HK1029278A1 (de)
IL (2) IL134669A0 (de)
NO (1) NO326479B1 (de)
NZ (1) NZ502983A (de)
PT (1) PT1017381E (de)
WO (1) WO1999009972A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1316309A1 (de) * 1998-12-23 2003-06-04 Orphan Medical Inc. Mikrobenbeständige und stabilisierte Lösungen die gamma-Hydroxybuttersäuresalze zur Behandlung von Narkolepsie enthalten
WO2000038672A2 (en) 1998-12-23 2000-07-06 Orphan Medical, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
US6610324B2 (en) * 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
ATE292965T1 (de) * 1999-09-14 2005-04-15 Tepha Inc Therapeutische anwendung von polymere die gamma- hydroxybutyrat enthalten
ES2383673T3 (es) 2000-09-22 2012-06-25 Jpi Commercial, Llc Composiciones de gamma-hidroxibutirato que contienen portadores de hidrato de carbonos
US7553829B2 (en) * 2000-11-30 2009-06-30 Humanetics Corporation Treatment of chronic fatigue syndrome and fibromyalgia syndrome
US20040259909A1 (en) * 2001-10-16 2004-12-23 Mccarthy Dennis Treatment of fibromyalgia syndrome
US20100324441A1 (en) * 2002-02-04 2010-12-23 Hargrove Jeffrey B Brain-Related Chronic Pain Disorder Treatment Method and Apparatus
US6703216B2 (en) 2002-03-14 2004-03-09 The Regents Of The University Of California Methods, compositions and apparatuses for detection of gamma-hydroxybutyric acid (GHB)
EP1638615B1 (de) 2003-05-08 2014-10-29 Tepha, Inc. Medizinische polyhydroxyalkanoat-textilien und fasern
DK1778305T3 (da) 2004-08-03 2010-10-18 Tepha Inc Ikke-krøllende polyhydroxyalkanoatsuturer
KR20070100686A (ko) * 2004-09-07 2007-10-11 오르펀 메디칼, 인크. 개선된 ｇｈｂ 조성물
JP2008519847A (ja) * 2004-11-10 2008-06-12 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク 運動障害の治療方法
DE112006001234T5 (de) * 2005-05-16 2008-04-10 Johnson, Joseph, Knoxville Verfahren und Zusammensetzung zur Behandlung von ARG
US7838556B2 (en) * 2006-02-21 2010-11-23 University Of Maryland, Baltimore Ethers of 3-hydroxyphenylacetic acid as selective gamma-hydroxybutyric acid receptor ligands
US7943683B2 (en) 2006-12-01 2011-05-17 Tepha, Inc. Medical devices containing oriented films of poly-4-hydroxybutyrate and copolymers
CA2740029C (en) * 2008-05-16 2016-12-20 Axis, Inc. Pharmaceutical composition for treatment of fibromyalgia
US8771735B2 (en) * 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
DK2421808T3 (da) 2009-04-23 2013-11-04 Concert Pharmaceuticals Inc 4-Hydroxysmørsyreanaloger
WO2011119839A1 (en) 2010-03-24 2011-09-29 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
CN103370289B (zh) 2011-02-14 2015-09-09 康塞特医药品有限公司 4-羟基丁酸氘化类似物
CA2732479A1 (en) * 2011-02-14 2012-08-14 Concert Pharmaceuticals, Inc. 4-hydroxybutyric acid analogs
EP2961738B1 (de) 2012-11-14 2019-12-25 CJ CheilJedang Corporation Herstellung von salzen von 4-hydroxybutyrate mittels biobasierter rohstoffe
US8591922B1 (en) 2012-12-14 2013-11-26 Jazz Pharmacuticals, Inc. Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
WO2016025329A1 (en) 2014-08-15 2016-02-18 Tepha, Inc. Self-retaining sutures of poly-4-hydroxybutyrate and copolymers thereof
EP3230500A1 (de) 2014-12-11 2017-10-18 Tepha, Inc. Verfahren zur ausrichtung von multifilamentgarn und monofilamenten aus poly-4-hydroxybutyrat und copolymere davon
US10626521B2 (en) 2014-12-11 2020-04-21 Tepha, Inc. Methods of manufacturing mesh sutures from poly-4-hydroxybutyrate and copolymers thereof
DK3237044T3 (da) 2014-12-22 2019-12-09 Sanofi Aventis Deutschland Automatisk injektionsanordning med elektromagnetisk drivenhed
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
FR3049463B1 (fr) 2016-04-01 2019-07-05 Debregeas Et Associes Pharma Doses unitaires a liberation immediate de ghb ou de l'un de ses sels therapeutiquement acceptables administrees par voie orale et leur utilisation pour maintenir l'abstinence alcoolique
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
CN112004520A (zh) 2017-12-18 2020-11-27 特瑞斯制药公司 包括具有触发脉冲药物释放的胃内滞留筏形成***的调节释放药物粉末组合物
US11337920B2 (en) 2017-12-18 2022-05-24 Tris Pharma, Inc. Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release
US11666546B2 (en) 2017-12-18 2023-06-06 Tris Pharma, Inc GHB pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
KR20210094513A (ko) 2018-11-19 2021-07-29 재즈 파마슈티칼즈 아일랜드 리미티드 알코올-내성 약물 제형
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
AU2021362222A1 (en) 2020-10-16 2023-06-01 Jazz Pharmaceuticals Ireland Limited Treatment methods using ghb
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60168044A (ja) * 1984-02-10 1985-08-31 Sharp Corp 感湿素子
US4738985A (en) * 1986-03-19 1988-04-19 The University Of Toronto Innovations Foundations Pharmaceutical composition and treatment
JPH05262654A (ja) * 1992-03-18 1993-10-12 Kaken Pharmaceut Co Ltd 慢性疲労症候群治療剤
ITTO930510A1 (it) * 1993-07-09 1993-10-07 Walter Tarello Farmaci attivi contro la chronic fatigue syndrome (c.f.s.)
IT1266565B1 (it) * 1993-07-22 1997-01-09 Ct Lab Farm Srl Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico.
US5840331A (en) * 1995-06-07 1998-11-24 Arch Development Corporation Use of γ-hydroxybutyrate for the stimulation of sleep-related secretion growth hormone and prolactin

Also Published As

Publication number Publication date
IL134669A0 (en) 2001-04-30
US5990162A (en) 1999-11-23
JP2001513552A (ja) 2001-09-04
NO20000989L (no) 2000-04-03
WO1999009972A1 (en) 1999-03-04
JP3660587B2 (ja) 2005-06-15
PT1017381E (pt) 2005-06-30
EP1017381B1 (de) 2005-02-23
DE69829112T2 (de) 2005-08-25
AU737086B2 (en) 2001-08-09
ES2235355T3 (es) 2005-07-01
AU8923798A (en) 1999-03-16
CZ295248B6 (cs) 2005-06-15
HK1029278A1 (en) 2001-03-30
NO20000989D0 (no) 2000-02-28
CA2301723C (en) 2008-02-19
CZ2000741A3 (cs) 2000-09-13
NO326479B1 (no) 2008-12-15
IL134669A (en) 2006-08-20
DE69829112D1 (de) 2005-03-31
NZ502983A (en) 2001-08-31
EP1017381A1 (de) 2000-07-12
CA2301723A1 (en) 1999-03-04

Similar Documents

Publication Publication Date Title
ATE289508T1 (de) Butyrate derivaten zur behandlung von fibromyalgia und chronische müdigkeit-syndrom
BR9710536A (pt) Isobutilgaba e seus derivados para o tratamento da dor
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE461698T1 (de) Gaba-analoga zur verhütung und behandlung gastrointestinaler beschwerden
DE58902094D1 (de) Kombinationspraeparat zur behandlung von nervenzell-und nervenfasererkrankungen und verletzungen.
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE69634900D1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
NO951761L (no) Stabilt preparat for behandling av blodkoagulasjonssykdommer
DE69703689D1 (de) Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia
ATE238047T1 (de) Verwendung von n,n-bis (phenylcarbamoylmethyl) dimethylammoniumchlorid und derivaten davon zur behandlung von chronischem schmerz
RU94020410A (ru) Способ лечения или профилактики рвоты у млекопитающих и человека с использованием некоторых хинуклидиновых, пиперидиновых, азанорборнановых, этилендиаминовых производных и родственных им соединений
EE9700302A (et) Meetod maania ja bipolaarse häire raviks
DE69638281D1 (de) Anti-Interleukin-9 Antikörper oder Anti-Interleukin-9 Rezeptor Antikörper zur Behandlung von bronchialem Hyperreaktionsvermögen
DE69902520D1 (de) Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden
DK1291018T3 (da) Phosphonatananaloger til mannose-6phosphat og deres anvendelse i behandlingen af sår og fibrotiske lidelser
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
ATE369143T1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
DE68909750D1 (de) Vorrichtung zur therapeutischen behandlung von lumbago sowie lumbago/ischias.
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
ATE225181T1 (de) Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen
NO984196L (no) FremgangsmÕte for behandling av stoffmisbruk
NO984198L (no) FremgangsmÕte for behandling av aggresjon
ATE216884T1 (de) Verwendung von sulbutiamin zur behandlung von psychomotorischen oder psychointellektuellen beschwerden
EA199800818A1 (ru) Способ лечения бессонницы

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1017381

Country of ref document: EP